Intel 18A-P process enters risk production on schedule By Investing.com

Intel Foundry said its 18A-P process has entered risk production on schedule in 2025, with 9% higher performance at iso-power or 18% lower power at iso-performance versus Intel 18A. The update highlights technical progress in Intel’s turnaround, alongside longer-term research advances in CFETs, GaN-on-silicon integration, and ruthenium interconnects. The article also notes Intel shares at $117.05, up 516% over the past year, though the stock remains below its prior close of $124.57.

Analysis

INTC is the obvious beneficiary, but the more interesting read-through is to the advanced-node ecosystem: the market is starting to price Intel not as a lagging CPU vendor, but as a credible second source for frontier manufacturing. That matters because even a modest share of external foundry wins would create a multi-year flywheel: better utilization lowers unit costs, which improves process economics, which then supports more aggressive customer qualification and IP reuse.

The second-order effect is on TSM and NVDA/GOOGL supply-chain optionality. If Intel can be qualified as a backup for high-end parts, hyperscalers and AI chip designers gain leverage in pricing and capacity allocation; that should cap the scarcity premium embedded in leading-edge foundry capacity over the next 6-18 months. TSM remains structurally superior, but the valuation gap can compress if the market starts discounting “single-vendor risk” less aggressively.

Consensus is likely underestimating the gap between technology progress and revenue conversion. The node announcement is necessary, not sufficient: the stock can still overshoot on process milestones while the foundry P&L remains dilutive until customer tape-outs scale. Near term, the setup is more about sentiment and multiple expansion than EPS; over 2-4 quarters, any delay in customer wins or a failure to translate risk production into volume would quickly unwind the rerating.

The contrarian angle is that the move may already be too far ahead of fundamentals. With the stock priced for a meaningful turnaround, the market is implicitly assuming on-time execution, external foundry wins, and cleaner 2026 profitability all at once. That creates a fragile narrative: one miss on yield, customer qualification, or capex discipline could trigger a sharp de-rating even if the process roadmap remains intact.

Key Decisions for Investors

• Long INTC vs short TSM in a 3-6 month pair trade: expresses the thesis that Intel’s optionality is being re-rated faster than its earnings, while TSM’s scarcity premium may compress if backup capacity becomes more credible. Stop if TSM wins a major new AI capacity commitment or Intel delays customer qualifications.
• Buy INTC call spreads 3-6 months out, financed by selling further OTM calls: best risk/reward for a momentum-driven rerating where the upside is a continued multiple expansion rather than immediate EPS delivery. Use a structure that caps theta bleed if the stock stalls near current levels.
• Hedge the long-INTOX/execution-risk with a small short in semiconductor equipment names that are most dependent on a clean Intel capex ramp; if Intel’s foundry conversion slips, equipment revenue expectations can reprice faster than the broad index.
• For existing NVDA and GOOGL holders, reduce tail-risk exposure via a modest hedge in INTC or TSM relative-value terms over the next 1-2 quarters; the goal is to offset any supply-chain leverage loss if Intel becomes a meaningful alternative source.
• Do not chase the stock on headline strength above the recent high without evidence of external design wins; wait for tape-out/customer-qualification confirmations, because the next leg is likely driven by foundry revenue visibility rather than process milestones.